Elite Medical Center, Al Riyadh, Kingdom of Saudi Arabia.
J Refract Surg. 2012 May;28(5):341-5. doi: 10.3928/1081597X-20120316-01. Epub 2012 Mar 26.
To evaluate 1-year visual and topographic outcomes and safety and efficacy of corneal collagen cross-linking (CXL) combined with topography-guided photorefractive keratectomy (TG-PRK) to achieve near emmetropia in eyes with low-grade keratoconus.
Twenty-two eyes from 15 patients (11 women, 4 men) were included in a prospective, nonrandomized, noncontrolled clinical study. Mean patient age was 26.6±6.07 years (range: 19 to 40 years). Inclusion criteria were low-grade keratoconus with evidence of progression, transparent cornea, corrected distance visual acuity (CDVA) 0.8 (decimal) or better, corneal thickness >440 μm, and maximum keratometry readings (K-max) <51.00 diopters (D). All patients underwent simultaneous TG-PRK with CXL. Study parameters were uncorrected distance visual acuity, CDVA, manifest refractive error, manifest and topographic (corneal) astigmatism, patient satisfaction, and efficacy and safety of the treatment. Follow-up was 1 year.
After 1 year, statistically significant improvement was noted in all study parameters (P<.01). The safety and efficacy indices were 1.6 and 0.4, respectively. Patient satisfaction questionnaire showed that 91% were satisfied, 9% were not completely satisfied but believed they improved, and none were dissatisfied. Corneal topography demonstrated significant improvement in 55%, improvement in 36%, and minor improvement in 9% of cases. No cases progressed as evidenced by keratometry readings.
Simultaneous TG-PRK with CXL is an effective and safe treatment with remarkable visual and topographic outcomes in patients with low-grade keratoconus who meet the recommended inclusion criteria.
评估角膜胶原交联(CXL)联合地形引导性准分子激光角膜切削术(TG-PRK)治疗低度圆锥角膜实现近视矫正的 1 年视力和地形学结果、安全性和有效性。
22 只眼(15 例患者,11 名女性,4 名男性)纳入前瞻性、非随机、非对照的临床研究。患者平均年龄为 26.6±6.07 岁(19 至 40 岁)。纳入标准为进展性低度圆锥角膜、角膜透明、矫正远视力(CDVA)≥0.8(十进制)、角膜厚度>440μm、最大角膜曲率读数(K-max)<51.00 屈光度(D)。所有患者均行 TG-PRK 联合 CXL 治疗。研究参数包括未矫正远视力、CDVA、矫正屈光不正、显性和地形(角膜)散光、患者满意度以及治疗的有效性和安全性。随访 1 年。
1 年后,所有研究参数均有统计学显著改善(P<0.01)。安全性和有效性指数分别为 1.6 和 0.4。患者满意度问卷调查显示,91%满意,9%不满意但认为有改善,无不满意。角膜地形图显示 55%显著改善,36%改善,9%轻微改善。角膜曲率读数无进展。
对于符合推荐纳入标准的低度圆锥角膜患者,TG-PRK 联合 CXL 是一种有效且安全的治疗方法,可显著改善视力和地形学结果。